论文部分内容阅读
目的:检测BMP-2及其受体BMPRⅠA、BMPRⅠB和BMPRⅡ在上皮性卵巢癌中的表达并分析其对卵巢癌患者预后的影响。方法:应用免疫组化方法检测BMP-2及其受体BMPRⅠA、BMPRⅠB和BMPRⅡ在100例上皮性卵巢癌组织中的表达水平并通过病例随访分析其对卵巢癌患者术后5年存活率和生存时间的影响。结果:①BMP-2及其受体BMPRⅠA、BM-PRⅠB、BMPRⅡ的蛋白阳性染色主要集中在卵巢癌细胞胞浆中。②BMP-2、BMPRⅠB、BMPRⅡ阳性表达的上皮性卵巢癌患者术后5年存活率明显高于阴性表达者,且其术后平均存活时间明显长于阴性表达者。而BMPRⅠA与卵巢癌患者的术后5年存活率和平均生存时间无关。结论:BMP-2、BMPRⅠB和BMPRⅡ在上皮性卵巢癌组织中表达减弱或缺失可能预示着卵巢癌患者预后较差。
OBJECTIVE: To detect the expression of BMPRⅠA, BMPRⅠB and BMPRⅡ in epithelial ovarian cancer and to study the effect of BMP-2 and its receptors on the prognosis of patients with ovarian cancer. Methods: The expression of BMPRⅠA, BMPRⅠB and BMPRⅡ in 100 cases of epithelial ovarian cancer was detected by immunohistochemistry. The 5-year survival rate and survival rate of ovarian cancer patients were analyzed by case follow-up The impact of time. Results: (1) BMP - 2 and its receptor BMPR Ⅰ A, BM - PR Ⅰ B, BMPR Ⅱ protein staining mainly concentrated in the cytoplasm of ovarian cancer cells. ② The 5-year survival rates of BMP-2, BMPRⅠB and BMPRⅡpositive epithelial ovarian cancer patients were significantly higher than those of negative expression, and the average postoperative survival time was significantly longer than that of negative expression. The BMPRⅠA and ovarian cancer patients after 5-year survival rate and mean survival time has nothing to do. Conclusion: The decreased or absent expression of BMP-2, BMPRⅠB and BMPRⅡ in epithelial ovarian cancer may predict the prognosis of patients with ovarian cancer is poor.